Compare · IRIX vs MDT
IRIX vs MDT
Side-by-side comparison of IRIDEX Corporation (IRIX) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRIX and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $103.03B, about 5238.2x IRIX ($19.7M).
- Over the past year, IRIX is up 16.0% and MDT is down 8.8% - IRIX leads by 24.8 points.
- MDT has been more active in the news (22 items in the past 4 weeks vs 10 for IRIX).
- MDT has more recent analyst coverage (25 ratings vs 0 for IRIX).
- Company
- IRIDEX Corporation
- Medtronic plc.
- Price
- $1.13+0.90%
- $80.34+0.12%
- Market cap
- $19.7M
- $103.03B
- 1M return
- +7.66%
- +4.53%
- 1Y return
- +15.98%
- -8.78%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 1996
- News (4w)
- 10
- 22
- Recent ratings
- 0
- 25
IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest IRIX
- Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
- Chief Financial Officer Dizon Romeo R bought $2,688 worth of shares (2,400 units at $1.12), increasing direct ownership by 2% to 133,325 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R bought $2,899 worth of shares (2,521 units at $1.15), increasing direct ownership by 2% to 130,925 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R bought $2,808 worth of shares (2,400 units at $1.17), increasing direct ownership by 2% to 128,404 units (SEC Form 4)
- SEC Form SD filed by IRIDEX Corporation
- President and CEO Mercer Patrick covered exercise/tax liability with 19,233 shares, decreasing direct ownership by 5% to 372,774 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R bought $5,004 worth of shares (5,004 units at $1.00), increasing direct ownership by 4% to 126,004 units (SEC Form 4)
- SEC Form 10-Q filed by IRIDEX Corporation
- IRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Iridex Reports First Quarter 2026 Financial Results
Latest MDT
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey covered exercise/tax liability with 41,936 units of Ordinary Shares, decreasing direct ownership by 12% to 301,163 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 7,471 units of Ordinary Shares, decreasing direct ownership by 11% to 63,122 units (SEC Form 4)
- SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 2,840 units of Ordinary Shares, decreasing direct ownership by 7% to 38,689 units (SEC Form 4)
- Chief Accounting Officer Blomquist Denise L. covered exercise/tax liability with 237 units of Ordinary Shares, decreasing direct ownership by 2% to 14,737 units (SEC Form 4)
- Medtronic upgraded by BTIG Research with a new price target
- Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
- Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits